<DOC>
	<DOCNO>NCT01018381</DOCNO>
	<brief_summary>Hepatocellular carcinoma ( HCC ) sixth common cancer worldwide estimate 626,000 new case per year worldwide , account 5.7 % new cancer case . Although resection transplantation offer best 5-year survival rate , patient suitable surgery candidate . Other treatment include pericutaneous ethanol injection ( PEI ) , radiofrequency ablation ( RFA ) , transarterial oily chemoembolization ( TOCE ) , enhance survival rate aid shrinkage tumor . The low survival rate among HCC patient , 3-5 % , reflect inadequacy conventional therapy disease highlight necessity find new treatment modify current treatment . The hepatitis B virus ( HBV ) cause liver disease range severity mild illness last several week ( acute hepatitis B ) long-term chronic illness . An estimated 2 billion people infected HBV worldwide , result 350 million individual chronic , long-term liver infection . Patients chronic HBV infection great risk development cirrhosis , hepatic failure , HCC . There cure hepatitis B care mostly palliative . There several anti-viral interferon drug , Entecavir Interferon α therapy , help patient . However , drug costly , thousand dollar per year , widely available many country , especially develop world . Vaccination available effective recommend individual risk HBV infection . However , vaccination effective individual expose HBV . Hepatitis B closely link liver cancer , almost always fatal . MGN-3/Biobran arabinoxylan extract rice bran treat enzymatically extract Shiitake mushroom . MGN-3 demonstrate anti-cancer activity vivo mouse human . The present study carry examine whether combine current conventional treatment food supplement , arabinoxylan rice bran ( MGN-3/Biobran ) , may improve outcome disease increase survival rate patient HCC HBV . We hypothesize combinatory treatment conventional therapy MGN-3/Biobran augment therapeutic effect see patient treated conventional therapy alone .</brief_summary>
	<brief_title>Arabinoxylan Rice Bran ( MGN-3/Biobran ) Treatment Hepatocellular Carcinoma Hepatitis B C Infection</brief_title>
	<detailed_description>Objective ( ) : The objective study analyze data study examine biotherapeutic effect combine conventional therapy presence MGN-3/Biobran . The study focus treatment patient Vietnam hepatocellular carcinoma ( HCC ) Hepatitis B C. Purpose study : Aim 1 : The biotherapeutic effect combine conventional therapy natural , non-toxic arabinoxylan rice bran ( MGN-3/Biobran ) treatment patient HCC examine . Parameters investigation include , lifespan patient , progression disease ( tumor size ) , recurrence disease . Aim 2 : The biotherapeutic effect combine conventional therapy natural , non-toxic arabinoxylan rice bran ( MGN-3/Biobran ) treatment patient Hepatitis B virus ( HBV ) examine . Parameters investigation include alanine transaminase ( ALT ) level , HBV antigen level , HBV DNA level . Methodology : Study Design : Secondary analysis data `` The effect Biobran/Lentin Plus adjuvant therapy hepatocellular carcinoma chronic hepatitis B '' study . The study randomize control design conduct 6/2006 7/2008 108 Military Central Hospital , Hanoi , Vietnam Dr. Mai Hong Bang Principal Investigator . MGN-3/Biobran approve Vietnam Ministry Health import VISA No.12577/2005/CBCL-YT . Therefore , The 108 Military Central Hospital approve study treatment patient HCC hepatitis B . 1 . Hepatocellular Carcinoma ( HCC ) : Sixty-eight patient sex , male female , HCC divide two group : group 1 ( 38 patient ) treat conventional therapy plus MGN-3 3 year , group 2 ( 30 patient ) treat conventional therapy alone . At various interval end study patient assess follow : lifespan patient , progression disease ( tumor size ) , recurrence disease . 2 . Hepatitis B virus ( HBV ) : Sixty-two patient sex , male female , HBV divide two group : group 1 ( 32 patient ) treat conventional therapy plus MGN-3 3 year , group 2 ( 30 patient ) treat conventional therapy alone . Conventional therapy give anti-viral drug , Entecavir . Data collect every six month two year . Parameters investigation include : alanine transaminase ( ALT ) level , HBV antigen ( HeBAg ) , HBV DNA level . Patients treated standard treatment ( transarterial oily chemoembolization ( TOCE ) HCC ; Entecavir HBV ) combination experimental treatment , arabinoxylan rice bran ( MGN-3/Biobran ) compare control group give standard treatment alone . Standard treatment administer 3 year . The experimental treatment ( MGN-3/Biobran ) administer dose 1g/day 3 year . Patient characteristic measure : - Group : two group Group1 = Conventional therapy Group2 = Conventional therapy + MGN-3 - Age range patient : 30-68 year old - Gender : male female - Medical condition ( ) : Hepatitis infection : Hepatitis B : HCC HBV Hepatitis C : HCC Hepatitis B C : HCC - Number tumors/patient ( HCC study ) - Tumor size ( HCC study ) : measure cm . &lt; 3 cm 3-6cm &gt; 6cm - AFP level : HCC - ≤500 ng/ml &gt; 500 ng/ml - HBV viral load - ALT level : HCC - HBV &lt; 100 IU/ml 100-250 IU/ml : 37 patient &gt; 250 IU/ml : 15 patient - Tumor Recurrence - Patient Survival Intervention detail Treatment group ( ) : HCC - Intervention ( PEIT , TOCE , PEIT + TOCE , TOCE + RFA ) Intervention + MGN-3 HBV - Intervention ( Entecavir ) Intervention + MGN-3 Control ( ) : Intervention group serve control Co-interventions : Intervention + MGN-3 group Duration intervention : HCC - 3 year HBV - 2 year Who deliver intervention ? Dr. Mai Hong Bang doctor . A consultation deliver intervention patient Outcome measure HCC : ALT level , AFP level , tumor size , patient survival , recurrence HBV : ALT level , HBV DNA level , recurrence , patient survival , HBeAg seroconversion Methods assess outcome measure : ALT AFP level , HBV DNA level , HBeAg seroconversion : blood test Tumor size : ultrasonography radiography Patient survival : observation When measure ? Every 6 month Length follow-up : HCC - 3 year HBV - 2 year Inclusion criterion : HCC patient Criteria inclusion - Patient ≤3 tumor ( 1 tumor 12cm/ 2 tumor 5cm /or 3 tumor 3cm ) - Stage disease : Okuda I , II Child Pugh A , B - Liver biopsy : HCC positive - General condition : average/ good Chronic hepatitis B patient Criteria inclusion - Patient carry HBsAg 6 month - ALT equal 2 time ULN - HBV-DNA level : 104 ( log10 copies/ml ) HBeAg ( - ) patient 105 ( log10 copies/ml ) HBeAg ( + ) patient Exclusion criterion : HCC patient Criteria exclusion - Tumor size big ( 12 cm ) , multiple tumor ( 3 tumor diffuse tumor type ) - Prothrombin 60 % - Severe liver or/ renal insufficiency - Portal vein body thrombosis Chronic hepatitis B patient Criteria exclusion - Used immunotherapy corticotherapy 6 month - Pregnant woman Procedures : Upon approval IRB , data analyze use statistical analysis data publish peer-reviewed journal , data yet publish . We receive data PI ( Dr. Mai Hong Bang , MD Ph.D. , Associate Professor , Department Hepatogastroenterology ) . After receive IRB approval , conduct secondary analysis data . We receive data electronic file excel file format code book variable . We frequency data check data management prepare data analysis . We recode create new variable exist variable way prepare data analysis . Benefits subject : Conventional therapy HCC HBV , addition toxicity , substantially improve survival rate patient . The combination MGN-3/Biobran conventional therapy may improve survival rate patient decrease rate recurrence . Benefits Community : There disproportionately high incidence HCC develop country , 50 % HCC case occur Asia . Hepatitis B closely link liver cancer , almost always fatal . It estimate nearly 80 % liver cancer worldwide cause hepatitis B infection . Therefore , need new treatment minimal side effect combat disease . This study determine potential MGN-3/Biobran combine conventional therapy improve outcome disease .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Ethanol</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<criteria>Inclusion criterion : HCC patient Criteria inclusion Patient ≤3 tumor ( 1 tumor 12cm/ 2 tumor 5cm /or 3 tumor 3cm ) Stage disease : Okuda I , II Child Pugh A , B Liver biopsy : HCC positive General condition : average/ good Chronic hepatitis B patient Criteria inclusion Patient carry HBsAg 6 month ALT equal 2 time ULN HBVDNA level : 104 ( log10 copies/ml ) HBeAg ( ) patient 105 ( log10 copies/ml ) HBeAg ( + ) patient Exclusion criterion : HCC patient Criteria exclusion Tumor size big ( 12 cm ) , multiple tumor ( 3 tumor diffuse tumor type ) Prothrombin 60 % Severe liver or/ renal insufficiency Portal vein body thrombosis Chronic hepatitis B patient Criteria exclusion Used immunotherapy corticotherapy 6 month Pregnant woman</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>HCC</keyword>
	<keyword>HBV</keyword>
	<keyword>MGN-3</keyword>
	<keyword>BioBran</keyword>
	<keyword>Alternative Therapy</keyword>
</DOC>